Clinical experiences with the use of oxytocin injection by healthcare providers in a southwestern state of Nigeria

dc.contributor.authorEjekam, C.S.
dc.contributor.authorOkafor, I.P.
dc.contributor.authorAnyakora, C.
dc.contributor.authorOzomata, E.A.
dc.contributor.authorOkunade, K.
dc.contributor.authorOridota, E.S.
dc.contributor.authorNwokike, J.
dc.date.accessioned2022-01-18T11:24:59Z
dc.date.available2022-01-18T11:24:59Z
dc.date.issued2019
dc.descriptionScholarly articlesen_US
dc.description.abstractPostpartum hemorrhage (PPH) is a leading cause of maternal mortality in Nigeria and in most low- and middle-income countries. The World Health Organization (WHO) strongly recommends oxytocin as effective, affordable, and the safest drug of first choice in the prevention and treatment of PPH in the third stage of labor. However, there are concerns about its quality. Very high prevalence of poor-quality oxytocin, especially in Africa and Asia, has been reported in literature. Excessive and inappropriate use of oxytocin is also common in low-resource settings. Objective To assess clinical experiences with quality of oxytocin used by healthcare providers in Lagos State, Nigeria. Methods This was a descriptive cross-sectional study conducted in 2017, with 705 respondents (doctors and nurses) who use oxytocin for obstetrics and gynecological services recruited from 195 health facilities (public and registered private) across Lagos State. Data collection was quantitative, using a pretested self-administered questionnaire. Data analysis was performed with IBM SPSS version 21. Statistical significance was set at 5 percent (p<0.05). Ethical approval was obtained from Lagos University Teaching Hospital Health Research Ethics Committee. Results Only 52 percent of the respondents knew oxytocin should be stored at 2°C to 8°C. About 80 percent of respondents used oxytocin for augmentation of labor, 68 percent for induction of labor, 51 percent for stimulation of labor, and 78 percent for management of PPH. Forty-one percent used 20IU and as much as 10% used 30IU to 60IU for management of PPH. About 13 percent of respondents reported believing they had used an ineffective brand of oxytocin in their practice. Just over a third (36%) had an available means of documenting or reporting perceived ineffectiveness of drugs in their facility; of these, only about 12 percent had pharmacovigilance forms in their facilities to report the ineffectiveness. Conclusion The inappropriate and inconsistent use of oxytocin, especially overdosing, likely led to the high perception of medicine effectiveness among respondents. This is coupled with lack of suspicion of medicine ineffectiveness by clinicians as a possible root cause of poor treatment response or disease progression. Poor knowledge of oxytocin storage and consequent poor storage practices could have contributed to the ineffectiveness reported by some respondents. It is necessary to establish a unified protocol for oxytocin use that is strictly complied with. Continuous training of healthcare providers in medicine safety monitoring is advocated.en_US
dc.description.sponsorshipThis study was funded by the United States Agency for International Development (USAID) Mission in Nigeria through the Promoting the Quality of Medicines (PQM) Program of the United States Pharmacopeial Convention (USP) (awarded to CSE). CSE, EAO, IPO, KO and SEO are salaried employees of Lagos University Teaching Hospital, Nigeria. The United States Pharmacopeial Convention (USP) provided support in the form of salaries for authors CA and JN. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.en_US
dc.identifier.citationChioma Stella Ejekam, Ifeoma Peace Okafor, Chimezie Anyakora, Ebenezer A. Ozomata, Kehinde Okunade, Sofela Ezekiel Oridota, Jude Nwokike (2019). Clinical experiences with the use of oxytocin injection by healthcare providers in a southwestern state of Nigeria: A cross-sectional study. PLOS ONE https://doi.org/10.1371/journal.pone.0208367.en_US
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/10520
dc.language.isoenen_US
dc.publisherPLOS ONEen_US
dc.subjectHealth care provideren_US
dc.subjectClinical experienceen_US
dc.subjectUse of oxytocinen_US
dc.subjectPostpartum hemorrhage (PPH)en_US
dc.subjectResearch Subject Categories::MEDICINEen_US
dc.titleClinical experiences with the use of oxytocin injection by healthcare providers in a southwestern state of Nigeriaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Publication 2 Oxytocin .pdf
Size:
840.29 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: